8-K current report · filed Nov 16, 2026

Vir Biotechnology, Inc. (VIR) 8-K Current Report: November 16, 2026

Item 1.01Item 8.01Item EX-99.1Item EX-99.2VIR overview

Short answer

Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). $150 million common-stock offering: 15 million shares at $10.00 each.

Vir Biotechnology, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $150 million common-stock offering: 15 million shares at $10.00 each
  • Expected net proceeds $140.4 million, increasing to $161.5 million with full option exercise
  • Underwriters’ 30-day option for 2.25 million additional shares, creating potential further dilution
  • Expected November 16, 2026 closing, subject to customary conditions
  • Proceeds strengthen Vir’s cash resources, while new shares dilute existing shareholders

Item 8.01 · Other Events

  • Proposed common stock offering announced on November 12, 2026, signaling potential equity financing and shareholder dilution
  • Offering priced the same day, indicating the transaction advanced from proposal toward execution
  • Investors should review Exhibits 99.1 and 99.2 for offering size, price, proceeds and closing terms

Item EX-99.1 · Exhibit EX-99.1

  • Vir Biotechnology announced a proposed underwritten public offering of common stock, creating potential shareholder dilution
  • Underwriters may purchase up to 15% additional shares through a 30-day option
  • Offering size, price and terms remain unspecified, with completion dependent on market conditions
  • Proceeds could support clinical-stage hepatitis delta and oncology programs, but use of proceeds was not stated
  • Leerink Partners, Morgan Stanley and Evercore ISI are bookrunning managers

Item EX-99.2 · Exhibit EX-99.2

  • Public offering priced at $10.00 per share for 15,000,000 shares, raising expected gross proceeds of $150 million
  • Underwriter option for 2,250,000 additional shares, creating further potential dilution and capital
  • Vir receives all offering proceeds, supporting funding for clinical-stage hepatitis delta and oncology programs
  • Offering expected to close November 16, 2026, subject to customary conditions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Vir Biotechnology, Inc. 8-K filings

Get the next VIR 8-K as it lands

Follow VIR for push alerts, or ask the research agent what this filing means.